167 related articles for article (PubMed ID: 37179118)
1. Biological and immunological significance of DLL3 expression in different tumor tissues: a pan-cancer analysis.
Zhang Y; Shang L; Han J; Shen X; Liu H; Yang J; Shi H
Aging (Albany NY); 2023 Apr; 15(9):3427-3441. PubMed ID: 37179118
[TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
3. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
Wang Y; Gong H; Cao Y
Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
[TBL] [Abstract][Full Text] [Related]
4. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
[TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
6. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
7. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
Liu P; Wang X; Pan L; Han B; He Z
Front Immunol; 2022; 13():901784. PubMed ID: 35720327
[TBL] [Abstract][Full Text] [Related]
9. RecQ mediated genome instability 2 (
Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
11. Pan-Cancer Analysis Based on
Zhang Y; Wang S; Han S; Feng Y
Front Oncol; 2022; 12():844794. PubMed ID: 35359375
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
13. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
Front Immunol; 2022; 13():951247. PubMed ID: 35935945
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Expression and Prognostic Value of MSH2 in Pan-Cancer Based on Bioinformatics.
Qiu W; Ding K; Liao L; Ling Y; Luo X; Wang J
Biomed Res Int; 2021; 2021():9485273. PubMed ID: 34859104
[TBL] [Abstract][Full Text] [Related]
16. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival.
Ding J; Ji X; Liu L; Chen DZ; Luo N; Yu XT; Guo F
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7857-7876. PubMed ID: 37039902
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Pan-Cancer Analysis of MEIS1 in Human Tumors as Prognostic Biomarker and Immunotherapy Target.
Li H; Tang Y; Hua L; Wang Z; Du G; Wang S; Lu S; Li W
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836180
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
Liu XS; Chen YL; Chen YX; Wu RM; Tan F; Wang YL; Liu ZY; Gao Y; Pei ZJ
Sci Rep; 2024 Apr; 14(1):9881. PubMed ID: 38688977
[TBL] [Abstract][Full Text] [Related]
19. The prognostic and immunological effects of ZBTB7C across cancers: friend or foe?
Chen X; Jiang Z; Wang Z; Jiang Z
Aging (Albany NY); 2021 May; 13(9):12849-12864. PubMed ID: 33946045
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]